177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03490838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-label, Multi-center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients With Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-resistant Prostate Cancer, Following Previous Systemic Treatment
Study identification
- NCT ID
- NCT03490838
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Interventions
- 177Lu-PSMA-R2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 23, 2018
- Primary completion
- May 25, 2021
- Completion
- Jun 1, 2022
- Last update posted
- May 12, 2025
2018 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pheonix Molecular Imaging Center | Phoenix | Arizona | 85040 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Yale New Haven Children Hospital | New Haven | Connecticut | 06520 | — |
| Tulane Cancer Center Tulance Cancer | New Orleans | Louisiana | 70112 | — |
| John Hopkins University - Kimmel Comp. Cancer Center | Baltimore | Maryland | 21231 | — |
| National Institute of Health | Bethesda | Maryland | 20892 | — |
| Mount Sinai Hospital School of Medicine | New York | New York | 10029 | — |
| University of Wisconsin / Paul P. Carbone Comp Cancer Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03490838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03490838 live on ClinicalTrials.gov.